CLINICAL DATA
The ULTIMA Trial
SEATTLE II Trial
OPTALYSE PE
Nykamp-Laurich
CLINICAL DATA
The ULTIMA Trial
SEATTLE II Trial
OPTALYSE PE
Nykamp-Laurich
Vascular Surgery / Venous Thromboembolism Portal / Pulmonary Embolism / Clinical Data / The ULTIMA Trial

 

The ULTIMA Trial
EKOS Endovascular System PE Clinical Studies

 

 

Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis
for Acute Intermediate-Risk Pulmonary Embolism
Nils Kucher, MD et al. Circulation 2014; 129: 479-486

Randomisation

 

Key Results

RV/LV ratio significantly improved at 24 hours.
Reduction in RV/LV ratio significantly greater at 24 hours and improved at 90 days.
No deaths or significant bleeding complications.
Systolic RV dysfunction significantly improved.

 

RV/LV Ratio Significantly
Improved at 24 Hours
RV/LV Ratio Significantly  Improved at 24 Hours
Reduction in RV/LV Ratio Significantly
Greater at 24 Hours and Improved at 90 Days
Reduction in RV/LV Ratio Significantly Greater at 24 Hours and Improved at 90 Days
No Deaths or Significant
Bleeding Complications

No Deaths or Significant  Bleeding Complications
Systolic RV Dysfunction
Significantly Improved

Systolic RV Dysfunction  Significantly Improved


Conclusions

ULTIMA confirmed that a fixed-dose, ultrasound-assisted catheter-directed thrombolysis using EKOS regimen was superior to anticoagulation alone in improving RV dysfunction at 24 hours without an increase in bleeding complications.

 

 

Top